ERBB2 and breast carcinoma: Adverse events were reported in all patients, predominantly Grade I-II, with no new safety signals detected.<h4>Conclusions</h4>Consistent with findings from previous clinical trials, real-world evidence from this study confirms that trastuzumab deruxtecan exhibits efficacy in patients with advanced breast cancer across all HER2 expression statuses and safety profile is manageable.